Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 9/20 | 0.55 |
| ▸ | CDK4 | P11802 | 9/20 | 0.55 |
| ▸ | CCND1 | P24385 | 9/20 | 0.55 |
| ▸ | CDK2 | P24941 | 9/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.49 |
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | NOS3 | P29474 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840651 | 0.92 | CDK1 (0.56) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3835005 | 0.91 | CDK1 (0.49) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3836179 | 0.91 | CDK1 (0.52) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3839647 | 0.90 | CDK1 (0.46) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3841462 | 0.89 | CDK1 (0.61) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3835468 | 0.85 | CDK1 (0.65) | CDK1CDK4CCND1CDK2 | |
| SCHEMBL3840146 | 0.85 | CDK1 (0.55) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3841297 | 0.84 | CDK1 (0.74) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3835475 | 0.83 | CDK1 (0.54) | CDK1CDK4CCND1CDK2MAP4K4 | |
| SCHEMBL3835549 | 0.82 | CDK1 (0.45) | CDK1CDK4CCND1CDK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | claimed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | claimed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | claimed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | claimed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | disclosed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | CDK2, CCNA2, CDK6 | CDK1 6/4885CDK4 9/4885CCND1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.